Researchers map deep brain stimulation target for Alzheimer’s disease

Boston [US], December 14 (ANI): The fifth most common cause of death for persons over 65 is Alzheimer’s disease (AD). A relatively recent strategy tries to treat the brain, while many prospective treatments for neurodegenerative disease concentrate on creating medications to target major offenders.
A neurosurgical procedure called deep brain stimulation (DBS) uses electrical stimulation of brain circuits to treat the symptoms of conditions including Parkinson’s disease and obsessive-compulsive disorder. DBS has been used experimentally in AD patients with varying degrees of success and variability in cognitive outcomes. These various results could be the result of variations in electrode placements between people.
Researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, compared DBS targets in AD patients previously treated at seven international sites, finding that stimulating the intersection of two particular brain networks correlated with better patient outcomes than stimulating nearby sites. Findings are published in Nature Communications.
“Not many Alzheimer’s patients have been treated with DBS, and so isolating a targetable network and showing that it could be predictive of patient outcomes was exciting,” said corresponding author Andreas Horn, MD, PhD, of the Center for Brain Circuit Therapeutics. “We refined an optimal DBS site, which future clinical trials of DBS may now use, going forward. If more patients are stimulated at this region, we may see clearer evidence across the group supporting the effectiveness of DBS.”
With the collaboration of colleagues from Toronto Western Hospital and six other centres, forty-six patients with mild AD treated with DBS to the fornix (fx-DBS) were included in this study. The fornix is an essential structure involved in memory formation.
Brigham researchers developed software capable of precisely registering fx-DBS sites from individual patients into a standardized map of the brain. From there, the researchers calculated the target associated with optimal clinical outcomes and determined what modulations of local tracts and whole-brain networks led to the best results.
Cognitive improvement was associated with DBS to the direct interface between the fornix and bed nucleus of the stria terminalis (involved in emotional and behavioural responses), with tract connections to the circuit of Papez playing a role as well (this circuit connects to the hippocampus, a major centre for memory formation).
Using an approach inspired by the machine-learning literature, the researchers validated their findings in a test cohort of 18 patients, whose data had been excluded from the initial stages of the research. They developed a model that was able to accurately determine clinical outcomes in these 18 patients based on where electrodes had been placed during their fx-DBS procedures.
The authors emphasize that this was a retrospective study, and prospective validation is required to further confirm their findings. They emphasize that neurodegeneration will progress even in patients who respond well to fx-DBS, but the procedure can potentially ameliorate symptoms.
As clinical trials of DBS continue, the researchers are looking to collaborate further with centres that conduct DBS to better define targetable networks for AD. They are also interested in further studying the exact circuits involved in memory formation based on stroke lesions that lead to cognitive decline.
“The data we used in this study is unique, and it was an honour that the team entrusted us with it so that we could apply methods we have developed over the past ten years to identify the sites in the brain that matter most for DBS in AD,” Horn said. “This is still basic science, but it may give hope in terms of potential treatments that, if applied correctly, could lead to symptomatic improvements.” (ANI)